%0 Generic %A C.-K., Park %A I.-J., Oh %A Y.-D., Choi %A T.-W., Jang %A J.-E., Lee %A J.-S., Ryu %A S.-Y., Lee %A Y.-C., Kim %D 2018 %T Supplementary Material for: A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_A_Prospective_Observational_Study_Evaluating_the_Correlation_of_b_i_c-MET_i_b_Expression_and_b_i_EGFR_i_b_Gene_Mutation_with_Response_to_Erlotinib_as_Second-Line_Treatment_for_Patients_with_Advanced_Metastatic_Non-Small-Cell_Lun/5943214 %R 10.6084/m9.figshare.5943214.v1 %2 https://karger.figshare.com/ndownloader/files/10633141 %K EGFR %K c-MET %K Silver in situ hybridization %K Erlotinib %X Objectives: We aimed to evaluate the prevalence and predictive role of c-MET expression and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC). Methods: We prospectively recruited 196 patients with stage IV or recurrent NSCLC treated with erlotinib after failure of first-line chemotherapy. Immunohistochemistry was used to evaluate c-MET overexpression, silver in situ hybridization (SISH) to assess gene copy number, and real-time polymerase chain reaction to detect EGFR mutations, respectively, in tumor tissue. Results: The major histologic type was adenocarcinoma (66.8%). c-MET was overexpressed in 55.8% (87/156) and dominant in females as well as non-squamous histology. Although c-MET gene amplification and high polysomy were observed in 2.0% (3/152) and 11.2% (17/152), they did not correlate with any characteristics. EGFR mutation was detected in 13.1% (20/153). The objective response rate of erlotinib was higher (61.1 vs. 3.7%, p < 0.001) and the median progression-free survival (PFS) was longer (10.2 vs. 1.9 months, p < 0.001) in EGFR-sensitizing mutations. However, c-MET positivity did not show a significant correlation with response to erlotinib or PFS. Conclusion: We reconfirmed EGFR mutation as a strong predictive marker of NSCLC. However, c-MET positivity was not associated with response or PFS, although c-MET overexpression correlated with some clinical characteristics. %I Karger Publishers